EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Novel serum protein biomarker panel for early diagnosis of pancreatic cancer

Sooin Byeon, Matthew J McKay, Mark P Molloy, Anthony J Gill, Jaswinder S Samra, Anubhav Mittal, Sumit Sahni iD

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34928 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Sooin Byeon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health, Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Pancreatic Neoplasms, Early Detection of Cancer, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: PanKind, The Australian Pancreatic Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers. Late presentation of disease at the time of diagnosis is one of the major reasons for dismal prognostic outcomes for PDAC patients. Currently, there is a lack of clinical biomarkers, which can be used to diagnose PDAC patients at an early resectable stage. This study performed proteomic mass spectrometry to identify novel blood‐based biomarkers for early diagnosis of PDAC. Serum specimens from 88 PDAC patients and 88 healthy controls (60 discovery cohort and 28 validation cohort) were analyzed using data independent acquisition high resolution mass spectrometry to identify candidate biomarker proteins. A total of 249 proteins were identified and quantified by the mass spectrometric analysis. Six proteins were markedly (>1.5 fold) and significantly ( p < .05; q < 0.1) increased in PDAC patients compared to healthy controls in discovery cohort. Notably, four of these six proteins were significantly upregulated in an independent validation cohort. The top three upregulated proteins (i.e., Polymeric Immunoglobulin Receptor [PIGR], von Willebrand Factor [vWF], and Fibrinogen) were validated using enzyme linked immunosorbent assay, which led to selection of PIGR and vWF as a diagnostic biomarker panel for PDAC. The panel showed high ability to diagnose early stage (stage I and II) PDAC patients (area under the curve [AUC]: 0.8926), which was further improved after the addition of clinically used prognostic biomarker (Ca 19‐9) to the panel (AUC: 0.9798). In conclusion, a novel serum protein biomarker panel for early diagnosis of PDAC was identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorPancreatic NeoplasmsEarly Detection of CancerCarcinoma, Pancreatic DuctalProteomicsHumansFemaleMaleMiddle AgedAgedReceptors, Polymeric Immunoglobulinvon Willebrand FactorFibrinogenCase-Control StudiesAdultBlood Proteins

Stichwörter der Autor:innen

blood testsdiagnostic biomarkersmass spectrometrypancreatic ductal adenocarcinomaproteomics

Substanzen

Biomarkers, TumorReceptors, Polymeric Immunoglobulinvon Willebrand FactorFibrinogenBlood Proteins

Autor:innen und Institutionen

  • Faculty of Medicine and Health, Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia.
  • Kolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.
  • Bowel Cancer and Biomarker Laboratory, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
  • NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Australian Pancreatic Centre, St Leonards, Sydney, New South Wales, Australia.
  • Upper GI Surgical Unit, Royal North Shore Hospital and North Shore Private Hospital, St Leonards, New South Wales, Australia.

ORCID-Profile: Sumit Sahni

Förderung

  • PanKind, The Australian Pancreatic Cancer Foundation

Zitieren

APA

Byeon, S., McKay, M. J., Molloy, M. P., Gill, A. J., Samra, J. S., Mittal, A., & Sahni, S. (2024). Novel serum protein biomarker panel for early diagnosis of pancreatic cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.34928

Vancouver

Byeon S, McKay MJ, Molloy MP, Gill AJ, Samra JS, Mittal A, et al. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer. International Journal of Cancer. 2024. doi:10.1002/ijc.34928

BibTeX
@article{Byeon2024,
  author = {Byeon, Sooin and McKay, Matthew J and Molloy, Mark P and Gill, Anthony J and Samra, Jaswinder S and Mittal, Anubhav and Sahni, Sumit},
  title = {Novel serum protein biomarker panel for early diagnosis of pancreatic cancer},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34928}
}
Kostenlos starten →